10-Q: Longduoduo Company Limited Reports Q3 2025 Results: Revenue Declines Amid Economic Headwinds

Longduoduo Company Limited's Q3 2025 revenue decreased due to the receding pandemic boost and current economic challenges in China.

Summary

• Longduoduo Company Limited reported a net loss of $116,320 for the three months ended March 31, 2025, compared to a net income of $517,969 for the same period in 2024.
• Total revenue for the quarter was $777,720, a 57% decrease from $1,790,084 in the prior year, attributed to the subsiding pandemic recovery and economic downturn impacting customer health expenditures.
• Commission revenue from acting as a sales agent for Inner Mongolia Honghai Health Management Co., Ltd. contributed $748,996 to the total revenue.
• Cost of revenue for the quarter was $20,444, resulting in a gross profit of $757,276.
• Operating expenses decreased by 15% to $876,095, mainly due to reduced advertising and promotion expenses.
• For the nine months ended March 31, 2025, the company reported a net income of $325,775, compared to $995,541 for the same period in 2024.
• Total revenue for the nine-month period was $3,322,287, a 42% decrease from $5,718,060 in the prior year.
• The company's cash and cash equivalents increased to $1,456,125 as of March 31, 2025, with a working capital of $786,440.
• Management acknowledges material weaknesses in disclosure controls and procedures, including a small accounting staff, lack of expertise in complex accounting issues, and insufficient documentation of financial processes.
• The company is implementing plans to improve operations by adjusting operational policies and awaits economic recovery following government initiatives.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the decline in revenue and net income, as well as the identified material weaknesses in internal controls. However, the company is taking steps to improve operations and anticipates economic recovery.

Positives

• Cash and cash equivalents increased to $1,456,125 as of March 31, 2025.
• Working capital increased by $395,609 since June 30, 2024.
• Operating expenses decreased by 15% due to reduced advertising and promotion spending.
• The company is implementing plans to improve its operations by adjusting its operational policies.
• The company has reduced its accounts payable balance by $113,289.

Negatives

• Q3 2025 revenue decreased by 57% year-over-year, totaling $777,720.
• The company experienced a net loss of $116,320 for Q3 2025, compared to a net income of $517,969 in Q3 2024.
• For the nine months ended March 31, 2025, net income was $325,775, down from $995,541 in the same period last year.
• The company acknowledges material weaknesses in its disclosure controls and procedures.
• The company's Chief Financial Officer is not familiar with the accounting and reporting requirements of a U.S. public company.

Risks

• Economic downturn in China impacting customer health expenditures.
• Material weaknesses in disclosure controls and procedures.
• Uncertainty regarding the impact of U.S.-China relations on the company's ability to raise capital and market price of shares.
• Inability to generate sufficient cash flows from operations and/or obtain additional financing.
• The relatively small number of employees who are responsible for accounting functions prevents us from segregating duties within our internal control system.
• Our internal financial staff lack expertise in identifying and addressing complex accounting issues under U.S. Generally Accepted Accounting Principles.
• We have not developed sufficient documentation concerning our existing financial processes, risk assessment and internal controls.

Future Outlook

The company anticipates that its future liquidity requirements will arise from the need to fund its growth, pay current obligations, and future capital expenditures, with funding expected from cash generated from operations and additional funds from a public offering and/or debt financing. The company expects Zhang Liang, its majority shareholder, to continue to provide support in the future, if needed.

Management Comments

• Management believes that the government has recently introduced policies to promote economic recovery, but it may take some time for the situation to truly improve.
• The Company will continue to invest heavily in advertising and promotion expenses in the near future as it continues to establish and expand its brand and products and services.
• Also, the Company intends to improve its operations by adjusting its operational policies.

Industry Context

The report indicates a challenging economic environment in China impacting consumer health expenditures, which aligns with broader trends of economic slowdown and cautious consumer spending in the region. The company's shift towards commission-based revenue reflects a common strategy among smaller healthcare service providers to reduce risk and capital expenditure during uncertain times.

Comparison to Industry Standards

• It is difficult to compare Longduoduo's results directly to industry standards due to its unique business model combining healthcare services and commission-based sales in the specific region of Inner Mongolia and Beijing.
• Larger, more established healthcare companies like UnitedHealth Group or Ping An Healthcare typically have more diversified revenue streams and greater financial stability.
• Smaller companies in the Chinese healthcare sector often face challenges related to regulatory compliance, market access, and competition from larger players.
• The company's focus on preventive healthcare solutions aligns with a growing trend in the industry, but its ability to capitalize on this trend depends on its marketing effectiveness and operational efficiency.

Related Party Transactions

• Due from related parties consists of $13,778 due from Zhou Hongxiao, the CEO of the Company.
• Due to related parties consists of $2,329 due to Zhang Liang.

Stakeholder Impact

• Shareholders may be concerned about the decline in revenue and net income.
• Employees may be affected by adjustments in operational policies and potential changes in staffing.
• Customers may experience changes in service offerings as the company adjusts its operational policies.
• Suppliers may be impacted by the company's efforts to manage its accounts payable balance.

Next Steps

• The company intends to improve its operations by adjusting its operational policies.
• The company will continue to invest heavily in advertising and promotion expenses.
• The company anticipates that its future liquidity requirements will arise from the need to fund its growth, pay current obligations and future capital expenditures.
• The company expects Zhang Liang, its majority shareholder, to continue to provide support in the future, if needed.

Key Dates

Keywords

revenue, Longduoduo, financial results, net income, healthcare, commission revenue, operating expenses, cash flow, China, Q3 2025